By Stephen Nakrosis
Vincerx Pharma has terminated a reverse merger agreement with Oqory and its parent company Vivasor.
The company said Friday it terminated an approved term sheet signed as part of deal after Oqory ended an exclusivity provision. Vincerx said it will explore strategic options.
The agreement would have seen Oqory merge with Vincerx, resulting in a combined company 95% owned by Oroqy equity holders. The deal would also have seen Oqory-designated investors provide $1.5 million of interim financing to Vincerx.
The company said it will review strategic alternatives, including out-licensing, merger and acquisition opportunities, and winding down operations, among other options. Vincerx said it had about $3.9 million in cash as of Feb. 26, and expects to have enough cash to operate late into the second quarter of this year.
Shares of Vincerx closed the market session down 13% at $1.09. The stock plunged 98% in the past year.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
February 28, 2025 16:55 ET (21:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.